News publication
Everything we hold that biomelbourne.org published.
Every article we hold from biomelbourne.org.
Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.
Deals recorded from biomelbourne.org's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Pathios Therapeutics | Series B | 1 May 2024 | $25m |
Companies named in biomelbourne.org's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Canaan Partners | 1 | |
| Pathios Therapeutics | 1 |
Investors named in biomelbourne.org's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Brandon Capital | 1 | |
| Bristol-Myers Squibb | 1 |